Anebulo Pharmaceuticals, Inc. (ANEB): Nasdaq/NYSE listing notice — Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW

Anebulo Pharmaceuticals, Inc.

Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.
Company entered lock-up agreement with 22NW (Aron English) on Feb 24, 2025, restricting voting/sale of 10.1M shares until stockholder approval.
Nasdaq granted extension until April 10, 2025 to obtain stockholder approval; annual meeting scheduled April 4, 2025.
Joseph Lawler entities have agreed to vote in favor of removing lock-up restrictions, which would ratify the change of control.
Failure to obtain stockholder approval by April 10, 2025 may result in delisting from Nasdaq Capital Market.

item 1.01 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Anebulo Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding shareholders (rules 5635(b)).

Exchange: nasdaq
Notice: extension granted
Deficiency: shareholders
Rules: 5635(b)

Exact text from the filing

February 24, 2025, the Company received a letter from Nasdaq notifying it that based on the Compliance Plan submitted to Nasdaq, the Nasdaq Staff has determined to grant the Company an extension to regain compliance with Rule 5635(b), as described below. The Compliance Plan proposed that 22NW and the Company enter into an irrevocable lock-up agreement pursuant to which 22NW would agree not to vote, sell, transfer, pledge or otherwise dispose of the Shares until such time as the Company obtained stockholder approval of the removal of such restrictions. In addition, irrevocable instructions to t

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Anebulo Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders
Rules: 5635(b)

Exact text from the filing

February 20, 2025, the Company received a letter (the “Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to comply with Nasdaq Listing Rule 5635(b) (“Rule 5635(b)”), which requires stockholder approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company. Prior to the Private Placement, the Company had two directors, Joseph F. Lawler and Aron English, that each beneficially owned in excess of 40% of the Company’s outstanding shares of Common Stock; however immediately after consummation of t

View on SEC.gov

Browse all listing & compliance notices →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-008080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.